Diabetes, a significant health issue leading to 1.5 million deaths in individuals under 70 in 2019, continues to escalate. Current GLP-1-based anti-diabetic peptides, while effective, are expensive, affecting public policy and social justice in middle and low-income nations. There's an urgent need for affordable, orally administrable peptides. Mr. LO Tak Ho and his team are dedicated to discovering new metabolic factors for diabetes treatment. They've unearthed a novel gastric hormone that could potentially treat both type II and I diabetes orally. Its high bioavailability negates the need for chemical modification, lowering toxicity risks and development costs, thus providing hope for an affordable diabetes treatment.
001_OWS2024_FHSS_Tak LO_Image Slide_001_1496x842.jpeg
002_OWS2024_FHSS_Tak LO_Image Slide_002_1496x842.jpeg
